Many tumors express on their receptor tyrosine kinases vascular endothelial growth factor activity associated with angiogenesis. Inhibition of angiogenesis through reduction of tyrosine kinase activity is a promising strategy for cancer therapy. The present study aimed to determine the mechanism and potency of ethyl p-methoxycinnamate (EPMC) isolated from Kaempferia galanga as angiogenesis inhibitor.
INTRODUCTION
Tyrosine kinase receptors of many tumors express vascular endothelial growth factor (VEGF) activity connected with angiogenesis. (1) In the last decade, angiogenesis has been explored in depth as an interesting cancer therapeutic target, since angiogenesis is an important step in tumor growth and cancer metastasis. (2, 3) Drug resistance, increased tumor progression, and signs of drug toxicity such as bleeding, fatigue, hypertension and gastrointestinal perforation are the main clinical problems that occur in patients treated with angiogenesis inhibitors.
(1) Thus, the use of natural herbal alternative agents to constrain angiogenesis is quite crucial in cancer treatment. Ethyl p-methoxycinnamate (EPMC), a major constituent of Kaempferia galanga Linn. (local name: kencur, Fam. Zingiberaceae) has been used as sunscreen, (4) analgesic (5) and antiinflammatory. (6, 7) agent, as cyclooxygenase-2 (COX-2) inhibitor, and to treat fibrosarcoma in mice. (8) It is has been established that PGE 2 production in preclinical breast and colon cancer models is strongly influenced by COX-2 expression. COX-2 inhibition augments VEGF pathway blockade to destroy angiogenesis and tumor growth, avoid metastasis, and increase overall patient survival. (9) (10) (11) It has also been reported that EPMC exerts anti-angiogenic activity in zebrafish (12) and can block endothelial function. (6) One method for the study of anti-angiogenic activity is by means of the chorio-allantoic membrane (CAM) model. The CAM is an extra-embryonic membrane formed on day 4 of incubation by fusion of the chorion and the allantois. The CAM contains extracellular matrix proteins that mimic the physiological cell environment and vascularization of cancers. Use of CAM has the advantages of easy accessibility and low cost, and is less time consuming. (13, 14) The present study was done because there have been no reports of the potency of EPMC to inhibit angiogenesis in the CAM model.
He et al. (12) reported that EPMC influences multiple molecular targets of angiogenesis, therefore we evaluated the possibility of EPMCmediated tyrosine kinase inhibition by performing a virtual molecular docking study using the Molegro Virtual Docker program (PDB 1XKK). The objectives of our study were to determine the antiangiogenic potency of EPMC and to predict whether the mechanism of action of this compound is related to its interaction with tyrosine kinase.
METHODS

Research design
This laboratory experimental study was conducted from May 2014 until September 2014. The research was performed in three steps, i.e. molecular docking study, isolation of EPMC from Kaempferia galanga and antiangiogenic assay using the CAM model.
Docking study
Molecular docking studies of EPMC, celecoxib and the reference ligand FMM_91 [A] (lapatinib tosylate) into the three-dimensional tyrosine kinase structure were carried out using Molegro Virtual Docker (MVD) software version 5.5. The receptor tyrosine kinase structure was obtained from the Protein Data Bank (PDB 1XKK). Ligand preparation was done using ChemBio Ultra software version 10.0.; the geometry was optimized by the MMFF 94 method and saved in Sybyl Mol2 format. All ligands were placed into the binding site of 1XKK (cavity-1) by alignment with the reference ligand FMM_91[A]) and 10 independent runs were performed. (15, 16) The binding affinity between ligand and enzyme (docking score) was predicted using rerank scores. 
Isolation of ethyl-p-methoxycinnamate from
Kaempferia galanga
Kaempferia galanga Linn. was collected and determined by the botanist at Materia Medica Botanical Garden Park at Batu (near Malang), Indonesia, in August 2013. EPMC was isolated from Kaempferia galanga Linn. by extraction of the dried powder of the rhizomes (1kg) with petroleum ether until the filtrate was nearly transparent. (6) The extract was filtered and concentrated in a Rotavapor Model Laborota 4000 vacuum evaporator (Heidolph Instruments, Germany) at 25°C, and then kept in the freezer. The extract was carefully washed with n-hexane, and the n-hexane supernatant was then decanted. This process was repeated until the solvent was almost transparent. (6) The residue that remained after washings consisted of pale yellow, needlelike crystals, which were recrystallized with ethanol 70%, yielding white pure EPMC crystals (10.2 g), with a sharp melting point of 49°C, as observed using a Fisher-John melting point apparatus. The chemical structure was characterized spectroscopically using a Jasco Fourier transform infra red (FT-IR) 5300 spectrophotometer and a nuclear magnetic resonance (NMR) Hitachi R-1900 spectrometer, confirming its identity as EPMC.
The 
Antiangiogenic activity of EPMC
Twenty-four nine-day old chicken eggs were obtained from PUSVETMA Surabaya, and incubated at 37ºC and 60-70% humidity. After 1 d of incubation, a 1 cm 2 window was opened at the top of the egg and the air was aspirated from the air chamber with a rubber ball until the CAM came in contact with the eggshell membrane. On all CAMs of the experimental groups, induction of new blood vessels was performed with bFGF 60 ng dissolved in 60 mL of stock rh bFGF at a concentration of 1 ng/mL in a laminar air flow hood under aseptic conditions. The eggs were distributed in six groups; four groups were treated with EPMC at dosages of 30, 60, 90 and 120 µg; one group was treated with celecoxib 60 µg as the positive control group, and one group was left without any treatment except bFGF blood vessel induction as the negative control group. To verify EPMC antiangiogenic activity, a CAM assay was accomplished with certain modifications as described before. (13, 17) Sterile 5-mm diameter Whatman qualitative filter-paper disks containing bFGF alone, or supplemented with EPMC (at dosages of 30, 60, 90 and 120 µg) or with celecoxib 60 µg, were implanted onto the CAM of each embryo. The window was resealed with adhesive tape and the eggs were returned to the incubator until day 11 of chick embryo development. After that, the upper eggshell was removed and neovascularization as positive parameter was characterized by capillary branching of the main blood vessels onto the bFGF-containing paper disks. The capillaries attached at the edges and on the upper and lower surfaces of the paper disks. The neovascularization parameter was considered to be negative if no capillary blood vessel formation occurred on the edges and upper and lower surfaces of the disk. Those capillaries within 2,5 mm around the filter paper disk were observed and photographed. Neovascularization around the disk was counted by determining the number of capillary branching of the main CAM blood vessels onto the disk. In addition to macroscopic observation as mentioned above, we also carried out microscopic observations in the following way: the CAM was removed from the shell, 10% formalin was added as preservative, and the CAM was then prepared into histological slides and stained with Hematoxylin and Eosin (HE). (13, 17, 18) Endothelial cell formation in the neovascular capillaries was observed in CAM cross-sections using an inverted Nikon H600L phase contrast microscope. Endothelial cell counts were determined in five visual fields of each slide at 400x magnification and compared with positive and negative controls for subsequent analysis.
Statistical analysis
Significant differences between the treatment and control group were assessed by one-way analysis of variance (ANOVA), supported by LSD test. Differences were considered significant at p<0.05.
Ethical clearance
This assay was approved by the Ethical Commision of Airlangga University.
RESULTS
The results of the molecular docking study (rerank scores) were -87. Figure 1 . Lapatinip tosylate displayed hydrogen bonding interaction between the following pairs: oxygen of ether moiety vs. Leu792; nitrogen of amino moiety and oxygen of furan ring vs Thr790; nitrogen of quinazoline ring vs. Lys745; oxygen of sulphonyl moiety vs. Gln791 and Lys852. Celecoxib presented hydrogen bonding interaction of the sulphonamide moiety with Ala743, Gln791 and Leu792. However, it showed steric and hydrophobic interaction of the trifluoromethyl moiety with Leu844, of the aromatic ring with Lys745, Ala743, and Met793, and of the sulphonamide moiety with Val742, Gln791 and Leu792 amino acid residues. EPMC showed hydrogen bonding interaction of the oxygen moiety with Met793, and steric and hydrophobic interaction of the Met766, Thr854, Thr790, Gln791 and Ala743 of tyrosine kinase. It was concluded that functional groups of EPMC can interact with some tyrosine kinase amino acids, similar to those of celecoxib and lapatinib tosylate.
Treatment of CAM bFGF-induced neovascularization with celecoxib 60 µg caused endothelial cell lysis of the blood vessels and reduced CAM neovascularization. Celecoxib suppressed CAM neovascularization by 83.4 ± 5.3% and growth of endothelial cells in capillary branches by 76.8 ± 2.2%. The potency of EPMC as angiogenic inhibitor was dose-dependent. At doses of 30, 60, 90 and 120 µg, EPMC inhibited neovascularization by 50.3 ± 4.5%, 67.6 ± 4.9%, 77.6 ± 6.3%, and 81.9 ± 3.2% (p<0.05) respectively. At the doses of 30, 60, 90 and 120 µg, EPMC inhibited endothelial cell counts in capillary branches of CAM by 50.9 ± 4.1%, 55.4 ± 2.9%, 66.1 ± 4.7%, and 73.2 ± 4.5%, respectively (p<0.05) ( Table 1 ). Table 1 . Antiangiogenesis activity of EPMC by treatment group using CAM model All values are represented as the mean ± SD (n=4) and indicate significant differences compared with the control-untreated group at p<0.05
The endothelial cell counts of CAM bFGFinduced capillaries in the negative control group were higher than in the EPMC-treated groups (Figure 2) .
Treatment of CAM with EPMC caused lysis of the endothelial cells (Figure 3) . The higher EPMC doses caused more endothelial cell lysis and decreased CAM neovascularization more strongly. EPMC as an antiangiogenic agent at doses of 30 and 60 µg was less active compared to celecoxib 60 µg. There were a statistically significant differences in antiangiogenic potency between EPMC doses of 90 and 120 µg. There were also a significant differences between celecoxib 60 µg and EPMC at doses 90 and 120 µg (p<0.05).
DISCUSSION
Angiogenesis plays an important role in delivering oxygen and nutrients essential for tumor progression and invasion of surrounding tissues and vessels. The development of a new vascular network consists of several steps which are controlled by various endogenous stimulators and inhibitors. (18) Antiangiogenic therapy has great potential for developing new cancer treatment methods in the future. 
A B C
He et al. (12) found by semiquantitative reverse transcription polymerase chain reaction assay that EPMC influences multiple molecular targets connected to angiogenesis. A recent study, showed the chemopreventive effect of EPMC against fibrosarcoma in mice and EPMC's capability to interact with COX-2. (8) The results of our molecular docking study on EPMC's interaction with the tyrosine kinase receptor (PDB 1XKK) predict the probable mechanism of EPMC as a cancer chemopreventive agent.
Molecular docking is a virtual method, in which the ligand is placed on the binding site in such a manner as to obtain the lowest potential energy. The docking process consists of testing the coordinate area of the target binding mode and scoring each possible ligand pose into that site. The lowest value of rerank scores is expected as the best binding mode. (15) Our results are in line with those of previous studies and tyrosine kinase is one of the molecular targets of EPMC for inhibition of angiogenesis. Altun et al. (20) reported that tyrosine kinase inhibitors are excellent agents for treating colorectal cancer and angiogenesis in a CAM model.
It is known that COX-2 may indirectly provoke angiogenesis by increasing the production of angiogenic factors, such as vascular endothelial growth factor (VEGF). (18, 19) Our study also supports the antiangiogenic activity of the COX-2 inhibitor celecoxib in the CAM assay. Several reports revealed that there is a significant association between COX-2 expression and VEGF-C expression. The combination of celecoxib with tamoxiven is a potential drug for treatment of breast cancers expressing high levels of VEGF. (18) Celecoxib as COX-2 inhibitor has been reported to suppress angiogenesis and growth of secondary bone tumors. (19) Celecoxib overturns the expression of VEGF by constraining the production of PGE 2 and the stimulation of some signal transduction pathways by which the expression of VEGF is upregulated. (21) Basic FGF as a proangiogenic agent causes chronic inflammation that markedly increases the risk for the development of cancer, and therefore angiogenesis and VEGF signaling might pose an important link between inflammation and tumor development. (19, 20) Histopathological analysis showed the presence of inflammatory cells on CAM induced by bFGF. Even though not directly proinflammatory, bFGF synergistically forces inflammatory mediator-induced leukocyte recruitment, thus indicating the relationship between inflammation and angiogenesis. (22, 23) Angiogenesis is triggered by increased arachidonic acid production as a result of prostaglandin PGE 2 metabolism catalyzed by COX-2. Prostaglandin affects vascularization and the cancer metastatic process that encourages the expression of proangiogenic factors, such as VEGF and fibroblast growth factor (FGF). (24) A previous research study reported that EPMC blocked COX-2 expession in the T47D cell line and caused lysis of that cell line. (25) This fact strengthens our prediction of the ability of antiinflammatory substances like EPMC to block the starting step of angiogenesis. Therefore, the present study was designed to investigate the potential angiogenesis inhibitory effect of EPMC on CAM. The outcomes showed that EPMC is a potent antiangiogenic substance, therefore it can be used as a cancer chemopreventive agent, in agreement with our earlier report. Although the antiangiogenic activity of EPMC is lower than that of celecoxib, EPMC can be used as lead compound for developing agents with higher antiangiogenic activities. EPMC can also be combined with other antiangiogenic drugs, e.g. bevacizumab, or with COX-2 inhibitors, such as celecoxib, so reducing the dose and decreasing the side effects of the drugs. (1, 9) One limitation of this study is the virtual experimental study of interactions between EPMC and tyrosine kinase, which eliminated the lipophilic effect of the compound. So, in our future research the experiment will be conducted by in vitro studies based on the present results. We will also study the inhibition of VEGF expression on CAM using EPMC.
The clinical implication of this study is the availability of an easily obtainable natural compound as a cancer chemopreventive agent. Ethyl p-methoxycinnamate is easily obtained from Kaempferia galanga, therefore its use may lower the expected cost of cancer treatment and increase life expectancy.
CONCLUSIONS
Ethyl
p-methoxycinnamate has antiangiogenic potency and its activity is dosedependent. The antiangiogenic potency of EPMC is associated with its inhibition of tyrosine kinase.
